Transarterial Chemoembolization Combined with Apatinib for Treatment of Advanced Hepatocellular Carcinoma:Analysis of Survival and Prognostic Factors  

作　　者：Zi-yi LIU Xue-feng KAN Li-jie ZHANG Joyman MAKAMURE Qing LI Dan ZHAO Guo-feng ZHOU Gan-sheng FENG Chuan-sheng ZHENG Bin LIANG 

机构地区：[1]Department of Radiology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430022,China [2]Hubei Province Key Laboratory of Molecular Imaging,Wuhan,430022,China

出　　处：《Current Medical Science》2022年第5期1015-1021,共7页当代医学科学（英文）

基　　金：supported by the National Natural Science Foundation of China(No.81771950,No.81471765 and No.81601578).

摘　　要：Objective Apatinib is a novel inhibitor of vascular endothelial growth factor receptor-2.The goal of this study was to evaluate overall survival(OS)after a combination of transarterial chemoembolization(TACE)and apatinib in patients with advanced hepatocellular carcinoma(HCC)and to identify the factors affecting patient survival.Methods Fifty-one patients with advanced HCC who received TACE in combination with apatinib in our hospital from June 2015 to May 2017 were enrolled.The OS and progression-free survival(PFS)were calculated using the Kaplan-Meier method.The log-rank test and Cox regression model were used to determine the factors affecting OS.Results The median OS and PFS of the patients were 15 months and 10 months,respectively.The 1-,2-,and 3-year survival rates were 64.7%,23.5%,and 1.8%,respectively.Univariate survival analysis showed that patients with Child-Pugh A(P=0.006),reduction rate of proper hepatic artery(P=0.016),hand-foot syndrome(P=0.005),secondary hypertension(P=0.050),and without ascites(P=0.010)had a better OS.Multivariate analysis showed that hand-foot syndrome(P=0.014),secondary hypertension(P=0.017),and reduction rate of proper hepatic artery(P=0.025)were independent predictors of better OS.Conclusion TACE combined with apatinib is a promising treatment for advanced HCC.Hand-foot syndrome,secondary hypertension,and the reduction rate of proper hepatic artery were associated with a better OS.

关 键 词：CHEMOEMBOLIZATION THERAPEUTIC apatinib molecular targeted therapy SURVIVAL factor analysis STATISTICAL 

分 类 号：R735.7[医药卫生—肿瘤]